BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Drug-Drug Interaction Study With Aricept® (Donepezil)
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT01042314
- Locations
- 🇺🇸
Parexel International - Baltimore Epcu, Baltimore, Maryland, United States
Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT01039194
- Locations
- 🇺🇸
Parexel International - Baltimore Epcu, Baltimore, Maryland, United States
Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 84
- Registration Number
- NCT01037166
- Locations
- 🇯🇵
Local Institution, Kyoto, Japan
An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 282
- Registration Number
- NCT01037062
- Locations
- 🇯🇵
Local Institution, Tokyo, Japan
Rollover Study of BMS-354825 in Patients With CML and Ph+ALL
Phase 1
Completed
- Conditions
- Chronic Myelogenous LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2010-12-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 54
- Registration Number
- NCT01030718
Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin
Phase 2
Completed
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 285
- Registration Number
- NCT01030432
- Locations
- 🇺🇸
Umass Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸Hospital Of The University Of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Alabama Liver & Digestive Specialists (Alds), Montgomery, Alabama, United States
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Phase 1
Completed
- Conditions
- Malignant Melanoma
- Interventions
- Drug: BMS-936558 (MDX1106-04)
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 127
- Registration Number
- NCT01024231
- Locations
- 🇺🇸
Memorial Sloan Kettering Nassau, New York, New York, United States
🇺🇸Medstar Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸Hillman Cancer Research Pavilion, Pittsburgh, Pennsylvania, United States
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2010-02-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 68
- Registration Number
- NCT01023204
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT01024062
Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT01024101
© Copyright 2025. All Rights Reserved by MedPath